AbSci Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 102
Employees
  • Latest Deal Type
  • Series E
  • Latest Deal Amount
  • $70M
Latest Deal Amount
  • Investors
  • 20

AbSci General Information

Description

Developer of biomanufacturing technologies intended to facilitate optimizable and scalable production of soluble recombinant monoclonal antibodies as well as other therapeutic proteins. The company engages in the development of novel production platforms for the large-scale production of recombinant proteins for therapeutic applications, enabling clients to reduce drug costs, accelerate development timelines and enable new biologic therapies to market.

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Technology Systems
Other Pharmaceuticals and Biotechnology
Discovery Tools (Healthcare)
Primary Office
  • 101 East 6th Street
  • Suite 350
  • Vancouver, WA 98660
  • United States
+1 (360) 000-0000

AbSci Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AbSci Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series E) 22-Feb-2021 $70M 00000 Completed Generating Revenue
8. Debt - PPP 28-Apr-2020 000.00 Completed Generating Revenue
7. Later Stage VC (Series D) 01-Feb-2020 0000 000.00 Completed Generating Revenue
6. Later Stage VC (Series C) 30-May-2018 0000 000.00 Completed Generating Revenue
5. Later Stage VC (Series B) 07-Aug-2017 00.00 Completed Generating Revenue
4. Later Stage VC 11-Apr-2016 00.00 00.00 0000 Completed Generating Revenue
3. Accelerator/Incubator 01-Jan-2013 Completed Generating Revenue
2. Grant Completed Generating Revenue
1. Angel (individual) Completed Generating Revenue
To view AbSci’s complete valuation and funding history, request access »

AbSci Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of biomanufacturing technologies intended to facilitate optimizable and scalable production of soluble recombi
Drug Discovery
Vancouver, WA
102 As of 2021
00000
00000000000 00000

0000000

onsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut en
0000000000000
Leiden, Netherlands
00 As of 0000
0000000000

0000000

ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
0000 00000000
San Francisco, CA
0 As of 0000
000 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AbSci Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Batavia Biosciences Corporation Leiden, Netherlands 00 0000000000
0000000 Formerly Accelerator/Incubator backed San Francisco, CA 0 000000&0
0000000 Formerly VC-backed Rockville, MD 000 000.00 000000000 -
000000 00000000000 Corporate Backed or Acquired Richmond, CA 000000000 -
00000000 Venture Capital-Backed Düsseldorf, Germany 00 0000000000
You’re viewing 5 of 29 competitors. Get the full list »

AbSci Executive Team (9)

Name Title Board Seat Contact Info
Sean McClain Co-Founder, Chief Executive Officer and Board Member
Shelley Klassen Co-Chief Financial Officer
Andreas Pihl Chief Operating Officer & Board Member
Matthew Weinstock Chief Technology Officer
Suzanne Sprunger Ph.D Senior Intellectual Property Officer
You’re viewing 5 of 9 executive team members. Get the full list »

AbSci Board Members (11)

Name Representing Role Since
Amrit Nagpal Redmile Group Board Member 000 0000
Andreas Pihl AbSci Chief Operating Officer & Board Member 000 0000
Daniel Gold Ph.D AbSci Board Member 000 0000
Eli Casdin Casdin Capital Board Member 000 0000
Gustavo Mahler Ph.D Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

AbSci Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AbSci Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ArrowMark Partners Asset Manager Minority 000 0000 000000 0
Casdin Capital Hedge Fund Minority 000 0000 000000 0
Merck Global Health Innovation Fund Corporate Venture Capital Minority 000 0000 000000 0
Redmile Group Hedge Fund Minority 000 0000 000000 0
Brian Vierra Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 20 investors. Get the full list »

AbSci Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 12-Jan-2021 000000000000000000 Decision/Risk Analysis 0000 0000000
To view AbSci’s complete acquisitions history, request access »

AbSci Subsidiaries (1)

Company Name Industry Location Founded
00000000 Decision/Risk Analysis San Diego, CA 0000
To view AbSci’s complete subsidiaries history, request access »